Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06129591 · ClinicalTrials.gov registry record · Phase 1
Topical CBD Scar Healing Study
A Phase 1 study, sponsored by University of Oklahoma.
- Not yet
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT06129591 is a Phase 1 study that has not yet begun recruiting, run by University of Oklahoma. The registered enrollment target is 22 participants.
The verdict
NCT06129591, a Phase 1 study, has not yet begun recruiting, sponsored by University of Oklahoma.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects (good and bad) that cannabidiol (CBD) has on scar healing and appearance in patients who have undergone paramedian forehead flap reconstruction.
Interventions
- DRUG Vantage Hemp CBD Isolate + Silicone patch
- DRUG Silicone patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2026-05 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06129591
The ClinicalTrials.gov registry entry for NCT06129591 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vantage Hemp CBD Isolate + Silicone patch is the first listed.
NCT06129591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06129591 about?
NCT06129591 is a clinical study titled "Topical CBD Scar Healing Study". The purpose of this study is to find out what effects (good and bad) that cannabidiol (CBD) has on scar healing and appearance in patients who have undergone paramedian forehead flap reconstruction.
What is the current status of trial NCT06129591?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2026-05. Estimated completion is 2028-07.
What interventions are being tested in trial NCT06129591?
The interventions under investigation include: Vantage Hemp CBD Isolate + Silicone patch (DRUG), Silicone patch (DRUG).
Who is sponsoring clinical trial NCT06129591?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.